Background GLP-1 receptor agonists (GLP-1 RAs) with exenatide bid first approved to treat
type 2 diabetes in 2005 have been further developed to yield effective compounds …

The incretin hormones glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐
like peptide‐1 (GLP‐1) have their main physiological role in augmenting insulin secretion …

Glucose levels in blood must be constantly maintained within a tight physiological range to
sustain anabolism. Insulin regulates glucose homeostasis via its effects on glucose …

Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)
are two gut hormones, defined incretins, responsible for the amplification of insulin secretion …

In recent years, glucagon-like peptide 1 receptor agonists (GLP-1RAs) have become central
in the treatment of type 2 diabetes (T2D). In addition to their glucose-lowering properties with …

ABSTRACT Introduction: Healthcare providers (HCPs) see many patients with obesity-
related complications and are therefore well placed to help treat obesity itself. However …

Erectile dysfunction (ED) is a long-term complication of type 2 diabetes (T2D) widely known
to affect the quality of life. Several aspects of altered metabolism in individuals with T2D may …

Hyperglucagonemia is a well-known contributor to diabetic hyperglycemia, and glucagon-
like peptide 1 (GLP-1) suppresses glucagon secretion. Reduced inhibitory effects of glucose …

A relatively recent addition to the arsenal of antidiabetic drugs used for the treatment of type
2 diabetes mellitus (T2DM) has been the “incretin mimetics,” a group of drugs that work on …

Background. Over the last few years, the use of sodium‐glucose cotransporter 2 inhibitors
(SGLT2i) and glucagon‐like peptide 1 receptor agonists (GLP‐1RA) has increased …